RVPH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.062

-58.89%

-0.083

-36.54%

-0.092

-22.92%

Estimates Revision

The market is revising No Change the revenue expectations for Reviva Pharmaceuticals Holdings, Inc. (RVPH) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -47.68%.

EPS Estimates for FY2025

Revise Downward

-22.35%

In Past 3 Month

Stock Price

Go Down

-47.68%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast RVPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVPH is 5.14 USD with a low forecast of 2.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

2.00

Averages

5.14

High

16.00

Current: 0.000

Low

2.00

Averages

5.14

High

16.00

Roth Capital

Buy

downgrade

2025-12-23

Reason

Roth Capital

Price Target

2025-12-23

downgrade

Buy

Reason

Roth Capital lowered the firm's price target on Reviva Pharmaceuticals to $1.50 from $3 and keeps a Buy rating on the shares after the company's request to file an NDA without a second Phase 3 schizophrenia study was denied by the FDA. While "disappointed" about today's update, the firm notes that its base case scenario assumed a second Phase 3 study would be needed. The firm remains "optimistic" about brilaroxazine, but lowers its price target in anticipation of equity dilution as it notes that the company requires about $60M to $75M to execute the second Phase 3 study.

H.C. Wainwright

Buy

downgrade

$11 -> $4

2025-10-27

Reason

H.C. Wainwright

Price Target

$11 -> $4

2025-10-27

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Reviva Pharmaceuticals to $4 from $11 and keeps a Buy rating on the shares. The firm cites the company's two "highly dilutive" financing transactions in June and September for the target cut.

Chardan

NULL -> Buy

initiated

2025-09-29

Reason

Chardan

Price Target

2025-09-29

initiated

NULL -> Buy

Reason

Chardan initiated coverage of Reviva Pharmaceuticals with a Buy rating and $2 price target. The firm cites the potential of the company's lead asset brilaroxazine as a next-generation antipsychotic product for the Buy rating. Reviva's brilaroxazine is a \"real product\" that could get approval in schizophrenia and find a niche in a large but highly genericized market, the analyst tells investors in a research note.

D. Boral Capital

Jason Kolbert

Buy

downgrade

$3 -> $2

2025-09-19

Reason

D. Boral Capital

Jason Kolbert

Price Target

$3 -> $2

2025-09-19

downgrade

Buy

Reason

D. Boral Capital analyst Jason Kolbert lowered the firm's price target on Reviva Pharmaceuticals to $2 from $3 and keeps a Buy rating on the shares. The company has executed on back-to-back capital raises that provide $19M in gross proceeds and reinforce its near-term financial runway, the analyst tells investors in a research note. The firm says that while Reviva's balance sheet is strengthened, the company's dilution overhang has expanded.

Benchmark

Speculative Buy

downgrade

$14 -> $7

2025-09-15

Reason

Benchmark

Price Target

$14 -> $7

2025-09-15

downgrade

Speculative Buy

Reason

Benchmark lowered the firm's price target on Reviva Pharmaceuticals to $7 from $14 and keeps a Speculative Buy rating on the shares ahead of the completion of a meeting with the FDA scheduled for Q4 to discuss the future NDA submission for brilaroxazine, which the firm calls \"the next major catalyst for the shares.\" The data so far have demonstrated Brilaroxazine has better efficacy, fewer side-effects, higher patient compliance, and easy dosing compared to existing alternatives for the treatment of schizophrenia, says the analyst, who adds that the company will likely need additional capital in order to move its clinical programs forward.

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$7 -> $3

2025-08-18

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$7 -> $3

2025-08-18

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Reviva Pharmaceuticals to $3 from $7 and keeps a Buy rating on the shares after meeting with its management team regarding its Q2 performance and its commercial outlook. The company's upcoming FDA Type C meeting presents an intriguing scenario to buy the stock at the current price given the opportunity to bypass a second Phase 3 study, the analyst tells investors in a research note. Roth adds however that its price target cut reflects equity dilution and its discount cash-flow model updates.

Valuation Metrics

The current forward P/E ratio for Reviva Pharmaceuticals Holdings Inc (RVPH.O) is -0.89, compared to its 5-year average forward P/E of -3.21. For a more detailed relative valuation and DCF analysis to assess Reviva Pharmaceuticals Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.21

Current PE

-0.89

Overvalued PE

-0.53

Undervalued PE

-5.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RVPH News & Events

Events Timeline

No data

News

1.0

2025-12-29Globenewswire

Reviva Pharmaceuticals CEO to Present at Neuroscience Innovation Forum in San Francisco

1.0

2025-12-29Newsfilter

Reviva Pharmaceuticals CEO to Present at 9th Annual Neuroscience Innovation Forum

7.5

2025-12-26NASDAQ.COM

Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway

People Also Watch

Frequently Asked Questions

What is Reviva Pharmaceuticals Holdings Inc (RVPH) stock price today?

The current price of RVPH is 0.34 USD — it has decreased -7.1 % in the last trading day.

What is Reviva Pharmaceuticals Holdings Inc (RVPH)'s business?

Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

What is the price predicton of RVPH Stock?

What is Reviva Pharmaceuticals Holdings Inc (RVPH)'s revenue for the last quarter?

Reviva Pharmaceuticals Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Reviva Pharmaceuticals Holdings Inc (RVPH)'s earnings per share (EPS) for the last quarter?

Reviva Pharmaceuticals Holdings Inc. EPS for the last quarter amounts to -0.06 USD, decreased -76.00 % YoY.

What changes have occurred in the market's expectations for Reviva Pharmaceuticals Holdings Inc (RVPH)'s fundamentals?

How many employees does Reviva Pharmaceuticals Holdings Inc (RVPH). have?

Reviva Pharmaceuticals Holdings Inc (RVPH) has 14 emplpoyees as of January 10 2026.

What is Reviva Pharmaceuticals Holdings Inc (RVPH) market cap?

Today RVPH has the market capitalization of 39.73M USD.